You started semaglutide three weeks ago. The first week was fine, maybe some mild nausea. By week two, you haven’t had a bowel movement in four days — and then suddenly things go loose. You’re not sure if this is normal or if something is wrong.
This is one of the most common patterns people report on GLP-1 medications, and tracking what happens at each dose level may help you make sense of it.
The short answer
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) slow gastric emptying — the rate at which food leaves your stomach. That slower transit may lead to constipation, looser stool, or a confusing mix of both at different points during treatment. GI side effects are the most commonly reported category for these medications, more common than the weight-loss and appetite changes that dominate the conversation.
How GLP-1 medications affect digestion
GLP-1 receptor agonists mimic a natural gut hormone that signals your brain to reduce appetite and your stomach to empty more slowly. That slowing effect doesn’t stop at the stomach — it may affect motility throughout the digestive tract.
The result: food and waste move through your system at a different pace than your body is used to. For some people, that means harder, less frequent stool. For others, it means an initial bout of looser stool as the gut adjusts. And for many, it means both at different times.
| Effect | What you might notice | Typical timing |
|---|---|---|
| Slower gastric emptying | Feeling full longer, bloating | Early, often persistent |
| Reduced bowel frequency | Fewer bowel movements, harder stool | May build over weeks |
| Nausea | Mild to moderate, especially after meals | Usually improves within 2–4 weeks |
| Looser stool | Diarrhea episodes, especially early on | Often resolves faster than constipation |
Constipation on GLP-1s
Constipation tends to be the most persistent GI side effect. Clinical trial data suggests an average duration of around 47 days, though individual experience varies widely. The pattern often follows dose escalation: things may settle at one dose, then symptoms return when the dose increases.
Signs that constipation may be GLP-1-related:
- Fewer bowel movements than your baseline (tracking helps here)
- Stool shifts toward Types 1–2 on the Bristol chart
- Bloating and a feeling of incomplete evacuation
- Symptoms that appeared or worsened after starting or increasing the dose
If you haven’t had a bowel movement in five or more days, or if you develop severe abdominal pain, contact your provider — these may signal something that needs prompt attention.
Diarrhea on GLP-1s — and overflow diarrhea
Some people experience diarrhea early in treatment, which often resolves within a few weeks. But there’s a second, less obvious pattern: overflow diarrhea.
Overflow diarrhea happens when liquid stool leaks around a hard, backed-up mass in the colon. It can feel like diarrhea — urgent, watery — even though the underlying problem is constipation. This confuses many people and may lead to the wrong self-treatment (avoiding fiber when you actually need more of it, for example).
Clues that it might be overflow diarrhea rather than simple diarrhea:
- Watery stool alternating with days of no bowel movement
- Bloating and abdominal fullness alongside loose episodes
- Small amounts of liquid stool rather than large, full bowel movements
If this sounds familiar, mention it to your prescribing provider — it changes the management approach.
Practical management ideas
These are self-care suggestions, not medical advice. Always discuss changes with your provider.
- Hydration. Slower transit means your colon has more time to absorb water from stool. Keeping fluid intake steady may help — try the 7-day hydration consistency experiment as a structured starting point.
- Fiber — gradually. Soluble fiber (oats, psyllium, chia) may help soften stool. But adding too much too fast can worsen bloating. A slow ramp — perhaps 5–10 g per day increase over a week — is gentler.
- Gentle movement. A short walk after meals may support motility. It doesn’t need to be intense.
- Meal size. Smaller, more frequent meals may reduce the bloating and nausea that come with slowed gastric emptying.
How to track GLP-1 stool changes
The most useful thing you can do is log your stool patterns alongside your dose level. This turns scattered symptoms into a clear timeline your provider can actually use.
What to log daily:
- Bristol stool type
- Number of bowel movements
- Urgency (yes/no)
- Bloating or nausea (brief note)
- Current dose level and days since last dose change
After 2–4 weeks, compare your averages at each dose level. Many people discover that their GI symptoms follow a predictable dose-escalation curve: spike, settle, spike again at the next increase, settle again.
When to seek medical care
Most GLP-1 GI side effects are uncomfortable but manageable. Seek care for:
- No bowel movement for five or more days
- Severe or sudden abdominal pain (may indicate pancreatitis or bowel obstruction)
- Blood or black/tarry stool
- Fever, vomiting, or signs of dehydration
- Faintness or unexplained weight loss beyond what’s expected from the medication
- Symptoms that worsen rather than improve over 2–3 weeks at the same dose
These are not typical adjustment symptoms and deserve prompt evaluation.
Evidence note
GI side effects are well documented in semaglutide and tirzepatide clinical trials. Constipation, nausea, and diarrhea are among the most frequently reported adverse events. The 47-day average constipation duration comes from pooled trial data, though individual timelines vary significantly. This article draws on published clinical data and is not a substitute for guidance from your prescribing provider.